Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3977 - L-carnosine for prevention of oxaliplatin-induced neuropathy in colorectal cancer patients (pts)


09 Oct 2016


Poster display


Amr Saad


Annals of Oncology (2016) 27 (6): 497-521. 10.1093/annonc/mdw390


A.S.T. Saad1, R.M. Yehia2, S.S. Mostafa3, H.S. Elabhar3, M.F. Schaalan2

Author affiliations

  • 1 Clinical Oncology Department, Ain Shams university Faculty of medicine, 11361 - Cairo/EG
  • 2 Clinical Pharmacy Department, misr international university, faculty of pharmacy, 44673 - Cairo/EG
  • 3 Clinical Pharmacology Department, cairo university, faculty of pharmacy, 17854 - Giza/EG


Abstract 3977


The study aims at investigating the use of anti-oxidant L-carnosine for prevention of acute oxaliplatin neurotoxicity in colorectal cancer pts and to observe L-carnosine effect on Tumor necrosis factor alpha (TNF α) as a neuro-inflammatory cytokine.


This is a pilot study that recruited 60 pts using prospective randomized controlled design. Eligible Pts (non-diabetic) were randomly assigned to two arms. Arm A (30 pts) received FOLFOX-6 regimen (oxaliplatin, 5FU & leucovorin) and Arm B (30 pts) received FOLFOX-6 regimen and oral L-carnosine 1000 mg daily all along the treatment. All recruited pts were followed for three months, then both arms were analyzed for neuropathy incidence/grade and any additional toxicities according to NCI-CTC version 4. Pre-treatment and after 3 months TNF α serum levels were collected and tested.


No neuropathy were detected in 35.3% of pts in Arm B compared to only 3.3% in Arm A. Also 50 % of pts in Arm B developed grade I neuropathy compared to 36.7% in Arm A and only 2.9% of Arm B pts developed grade II neuropathy compared to 60 % of arm A pts. Regarding TNF α serum levels, Arm B and Arm A at base line had comparable mean serum levels (0.04ng/ml & 0.03ng/ml) however the percentage reduction of Arm B serum level was higher than Arm A (0.02ng/ml & 0.001ng/ml, respectively p value = 0.0001). No toxicities were observed due to L-carnosine addition.

Arm A and Arm B regarding the neuropathy grade and TNF before/after 3 months of treatment

Arm A (Control group) N = 30 Arm B (Test group) N = 30 P-value
Neuropathy grade 0 1 2 Drop out 1 (3.3%) 11 (36.7%) 18 (60.0%) 0 (0.0%) 12 (35.3%) 17 (50.0%) 1 (2.9%) 4 (11.8%) 0.0002
TNF before start of treatment (ng/ml) Mean ± SD Range 0.03 ± 0.01 0.021 – 0.06 0.04 ± 0.01 0.02 – 0.06 0.664
TNF after 3 months of treatment (ng/ml) Mean ± SD Range 0.03 ± 0.01 0.016 – 0.044 0.02 ± 0.01 0.01 – 0.04 0.0001


L-carnosine reduced the incidence of acute oxaliplatin induced neuropathy, delayed the onset of chronic neuropathy and decreased TNF α serum levels without additional toxicities. Further studies are warranted to examine the full potential of L-carnosine in chemotherapy induced neuropathy.

Clinical trial identification

Local registry: CairoUniv 387658

Legal entity responsible for the study

Faculty of Medicine, Ain Shams University


Faculty of Medicine, Ain shams university Misr international university


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings